Cytek Biosciences, Inc.
CTKB
$5.36
-$0.03-0.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.54% | -2.18% | -7.59% | -1.30% | 7.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.54% | -2.18% | -7.59% | -1.30% | 7.29% |
| Cost of Revenue | 9.99% | 2.62% | -2.50% | -5.40% | 8.03% |
| Gross Profit | -5.01% | -6.17% | -12.41% | 1.83% | 6.72% |
| SG&A Expenses | 18.90% | 7.11% | 6.08% | 5.50% | 4.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.29% | 1.96% | 1.51% | -2.19% | 2.44% |
| Operating Income | -116.38% | -24.59% | -39.51% | 381.75% | 33.83% |
| Income Before Tax | -5,048.41% | 5.72% | -25.28% | 151.11% | 103.75% |
| Income Tax Expenses | -192.22% | -136.70% | 104.82% | 148.85% | -134.52% |
| Earnings from Continuing Operations | -682.15% | 46.49% | -84.83% | 75.23% | 114.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -682.15% | 46.49% | -84.83% | 75.23% | 114.58% |
| EBIT | -116.38% | -24.59% | -39.51% | 381.75% | 33.83% |
| EBITDA | -203.46% | -29.99% | -44.99% | 49.93% | 48.48% |
| EPS Basic | -695.83% | 44.58% | -88.54% | 81.31% | 115.19% |
| Normalized Basic EPS | -5,542.86% | 2.34% | -27.97% | 94.79% | 103.65% |
| EPS Diluted | -695.83% | 45.00% | -80.00% | 73.48% | 114.40% |
| Normalized Diluted EPS | -5,542.86% | 2.34% | -27.97% | 94.79% | 103.65% |
| Average Basic Shares Outstanding | -2.64% | -3.43% | -1.97% | -3.34% | -3.80% |
| Average Diluted Shares Outstanding | -3.94% | -3.43% | -1.97% | -3.34% | -2.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |